New hope for aggressive uterine cancer: One-Year pill may keep disease at bay
NCT ID NCT06712472
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking a daily targeted therapy pill (olaparib) for one year after standard chemoradiation can prevent endometrial cancer from coming back in patients with a specific genetic change (p53 abnormal). About 554 participants will be randomly assigned to receive olaparib or just observation. The goal is to see if the drug improves how long patients stay cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib (a targeted therapy pill taken twice daily for one year)
- What this could lead to
- If successful, this could offer a new maintenance option to delay cancer recurrence in patients with a specific genetic subtype of endometrial cancer.
- What could go wrong
- This is an early-stage Phase 3 trial; results may not confirm benefit. Olaparib can cause side effects like fatigue, nausea, and blood count changes, and not all patients may tolerate it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU De LIMOGES
RECRUITINGLimoges, 87000, France
-
Centre Antoine LACASSAGNE
RECRUITINGNice, 06189, France
-
Centre Hospitalier D'Albi
RECRUITINGAlbi, 81000, France
-
Centre Hospitalier de Carcassonne
RECRUITINGCarcassonne, 11000, France
-
Centre LEON BERARD
RECRUITINGLyon, 69008, France
-
Chu Besancon
RECRUITINGBesançon, 25030, France
-
Chu Dijon
RECRUITINGDijon, 21000, France
-
Clinique Sainte Anne
RECRUITINGStrasbourg, 67000, France
-
Groupe Hospitalier Mutualiste de Grenoble
NOT_YET_RECRUITINGGrenoble, 38000, France
-
Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Hopital Cochin
NOT_YET_RECRUITINGParis, 75014, France
-
INSTITUT CANCEROLOGIE DE L'OUEST-St HERBLAIN
RECRUITINGSaint-Herblain, 44800, France
-
Institut Cancerologie de L'Ouest-Angers
RECRUITINGAngers, 49055, France
-
Institut Marie-Curie
RECRUITINGParis, 75005, France
-
Institut Paoli Calmettes
RECRUITINGMarseille, 13009, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?